MGNX
MacroGenics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+5/100
Last price
3.64
▼ 0.13 (3.45%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.80
Prev close
3.77
Day high
3.79
Day low
3.55
Volume
633.18K
Market cap
$231.87M
P/E (TTM)
—
52W range
1.29 – 5.08
Day trading desk
Gap from prior close
+0.72%
Prior close 3.77
VWAP
3.64
-0.06% from price
Relative volume
0.91×
Normal
Session range
6.96%
3.55 – 3.80
Position in range
36%
Mid range
ATR (14D)
0.22
6.17% of price
Prior day high
3.86
PDH
Prior day low
3.49
PDL
Bid / ask spread
—
Quote not published
Session volume
567.09K
Avg 624.59K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.45%
-5.4%
1M
-17.27%
-18.4%
3M
-21.89%
-26.4%
6M
+8.66%
-9.5%
YTD
+126.09%
+111.8%
1Y
+104.49%
+88.1%
3Y
-21.89%
-104.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on MGNX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+42.65K
Net buying
Buy transactions
10
73.75K shares
Sell transactions
1
31.11K shares
Net transactions
+11
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
2.22M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 19, 26 | PETERS JEFFREY STUART General Counsel |
SELL | 31.11K | $129.09K | Direct |
| Aug 17, 26 | BONVINI EZIO Officer |
CONVERSION | 40.00K | $104.00K | Direct |
| May 18, 26 | SIEGEL JAY PHILIP M.D. Director |
— | 3.75K | — | Direct |
| May 18, 26 | STUMP DAVID CARTER M.D. Director |
— | 3.75K | — | Direct |
| May 18, 26 | FERRANTE KAREN JEAN M.D. Director |
— | 3.75K | — | Direct |
| May 18, 26 | CHHABRA MEENU Director |
— | 3.75K | — | Direct |
| May 18, 26 | HURWITZ EDWARD Director |
— | 3.75K | — | Direct |
| May 18, 26 | O'BRIEN FEDERICA F Director |
— | 3.75K | — | Direct |
| May 18, 26 | HEIDEN WILLIAM K Director |
— | 3.75K | — | Direct |
| May 18, 26 | LIU MARGARET A Director |
— | 3.75K | — | Direct |
| May 18, 26 | JACKSON SCOTT THOMAS Director |
— | 3.75K | — | Direct |
| Feb 13, 26 | SPITZNAGEL THOMAS Officer |
— | 13.33K | — | Direct |
| Feb 13, 26 | PETERS JEFFREY STUART General Counsel |
— | 13.33K | — | Direct |
| Feb 13, 26 | SMITH BETH ANN Officer and Treasurer |
— | 1.09K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BONVINI EZIO |
Officer | 185.80K | Conversion of Exercise of derivative security |
ECK STEPHEN L |
Officer | 29.38K | Conversion of Exercise of derivative security |
FERRANTE KAREN JEAN M.D. |
Director | 14.75K | Conversion of Exercise of derivative security |
HEIDEN WILLIAM K |
Director | 114.75K | Conversion of Exercise of derivative security |
HURWITZ EDWARD |
Director | 47.82K | Conversion of Exercise of derivative security |
KARRELS JAMES |
Chief Financial Officer | 206.04K | Conversion of Exercise of derivative security |
KOENIG SCOTT |
Director | 867.24K | Conversion of Exercise of derivative security |
RISSER ERIC BLASIUS |
Chief Executive Officer | 77.17K | Conversion of Exercise of derivative security |
SIEGEL JAY PHILIP M.D. |
Director | 14.75K | Conversion of Exercise of derivative security |
SPITZNAGEL THOMAS |
Officer | 38.54K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$231.87M
Enterprise value$93.97M
Revenue (TTM)$175.14M
Gross profit$-1.30M
EBITDA$-32.17M
Net income$-101.06M
EPS (TTM)$-1.64
Free cash flow$-69.41M
Total cash$173.30M
Total debt$35.09M
Book value / share$0.67
Shares outstanding63.70M
Float56.42M
Short % of float11.44%
Dividend yield0.00%
Beta (5Y)1.21
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.48
PEG ratio—
Price / sales—
Price / book5.40
EV / revenue0.54
EV / EBITDA-2.92
Gross margin-0.74%
Operating margin-42.19%
Profit margin-8.33%
Return on equity-225.85%
Return on assets-8.05%
Debt / equity81.85
Current ratio2.96
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $149.50M | $149.96M | $58.75M | $150.02M | -0.3% |
| Operating revenue | $149.50M | $149.96M | $58.75M | $150.02M | -0.3% |
| Cost of revenue | $36.01M | $12.30M | $8.22M | $7.38M | +192.8% |
| Gross profit | $113.49M | $137.66M | $50.53M | $142.63M | -17.6% |
| Research & development | $147.17M | $177.19M | $166.58M | $207.03M | -16.9% |
| Selling, general & admin | $39.16M | $71.05M | $52.19M | $58.95M | -44.9% |
| Total operating expense | $186.33M | $248.24M | $218.77M | $264.05M | -24.9% |
| Operating income | -$72.84M | -$110.58M | -$168.24M | -$121.42M | +34.1% |
| Net interest income | -$2.45M | $8.31M | $8.26M | $1.66M | -129.5% |
| Pre-tax income | -$75.29M | -$66.02M | -$9.06M | -$119.76M | -14.0% |
| Tax provision | -$672.00K | $944.00K | $0 | $0 | -171.2% |
| Net income | -$74.62M | -$66.97M | -$9.06M | -$119.76M | -11.4% |
| Net income to common | -$74.62M | -$66.97M | -$9.06M | -$119.76M | -11.4% |
| Basic EPS | -1.18 | -1.07 | -0.15 | -1.95 | -10.3% |
| Diluted EPS | -1.18 | -1.07 | -0.15 | -1.95 | -10.3% |
| EBIT | -$66.78M | -$64.91M | -$7.63M | -$119.76M | -2.9% |
| EBITDA | -$59.61M | -$57.37M | $2.02M | -$107.89M | -3.9% |
| Basic shares | 63.16M | 62.62M | 61.93M | 61.43M | +0.9% |
| Diluted shares | 63.16M | 62.62M | 61.93M | 61.43M | +0.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $57.22M | $182.84M | $100.96M | $108.88M | -68.7% |
| Cash & short-term investments | $189.91M | $201.67M | $229.81M | $154.35M | -5.8% |
| Accounts receivable | $13.37M | $4.31M | $10.37M | $56.22M | +210.4% |
| Inventory | $7.91M | $0 | $1.22M | $1.45M | — |
| Total current assets | $219.94M | $217.49M | $251.34M | $222.18M | +1.1% |
| Property, plant & equipment | $35.52M | $42.61M | $45.69M | $56.91M | -16.6% |
| Total assets | $256.85M | $261.65M | $298.42M | $280.47M | -1.8% |
| Total current liabilities | $43.12M | $55.53M | $56.11M | $48.61M | -22.4% |
| Total debt | $36.76M | $37.46M | $33.97M | $34.83M | -1.9% |
| Total liabilities | $201.25M | $145.60M | $145.81M | $138.46M | +38.2% |
| Retained earnings | -$1.24B | -$1.17B | -$1.10B | -$1.09B | -6.4% |
| Shareholder equity | $55.59M | $116.06M | $152.61M | $142.01M | -52.1% |
| Working capital | $176.83M | $161.96M | $195.23M | $173.57M | +9.2% |
| Net tangible assets | $55.59M | $116.06M | $152.61M | $142.01M | -52.1% |
| Shares issued | 63.32M | 62.82M | 62.07M | 61.70M | +0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$74.62M | -$66.97M | -$9.06M | -$119.76M | -11.4% |
| Depreciation & amortisation | $7.17M | $7.54M | $9.64M | $11.87M | -4.9% |
| Stock-based compensation | $14.29M | $29.44M | $18.37M | $20.44M | -51.5% |
| Change in working capital | -$28.33M | $1.39M | $53.32M | -$6.13M | -2,135.3% |
| Operating cash flow | -$81.04M | -$68.37M | -$78.20M | -$86.96M | -18.5% |
| Capital expenditure | -$1.91M | -$3.71M | -$1.76M | -$3.62M | +48.4% |
| Investing cash flow | -$114.10M | $149.30M | -$80.08M | $70.72M | -176.4% |
| Financing cash flow | $69.51M | $960.00K | $150.36M | $1.66M | +7,141.0% |
| Free cash flow | -$82.95M | -$72.08M | -$79.97M | -$90.58M | -15.1% |
| End cash position | $57.22M | $182.84M | $100.96M | $108.88M | -68.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $32.83M | $20.77M | $41.23M | $72.84M | $6.87M | — | +58.0% |
| Operating revenue | $32.83M | $20.77M | $41.23M | $72.84M | $6.87M | — | +58.0% |
| Cost of revenue | — | $9.53M | $10.12M | $11.59M | $8.91M | $5.40M | — |
| Gross profit | — | $11.24M | $31.11M | $61.25M | $13.34M | $7.79M | — |
| Research & development | $38.78M | $34.97M | $33.97M | $32.71M | $40.79M | — | +10.9% |
| Selling, general & admin | $7.90M | $9.71M | $9.23M | $9.90M | $9.30M | — | -18.6% |
| Total operating expense | $46.68M | $44.68M | $43.21M | $42.61M | $50.09M | — | +4.5% |
| Operating income | -$13.85M | -$33.44M | -$12.10M | $18.64M | -$43.22M | — | +58.6% |
| Net interest income | -$3.03M | -$3.33M | -$2.83M | -$1.81M | $612.00K | — | +9.2% |
| Pre-tax income | -$69.64M | -$36.77M | -$14.93M | $16.82M | -$42.61M | — | -89.4% |
| Tax provision | $0 | — | -$777.00K | $0 | $105.00K | — | — |
| Net income | $19.52M | -$36.77M | -$14.15M | $16.82M | -$36.25M | — | +153.1% |
| Net income to common | $19.52M | -$36.77M | -$14.15M | $16.82M | -$36.25M | — | +153.1% |
| Basic EPS | 0.31 | -0.58 | — | 0.27 | -0.57 | -0.65 | +153.4% |
| Diluted EPS | 0.31 | -0.58 | — | 0.27 | -0.57 | -0.65 | +153.4% |
| EBIT | -$65.25M | -$31.89M | -$10.66M | $20.16M | -$41.81M | — | -104.6% |
| EBITDA | -$64.54M | -$30.20M | -$8.96M | $21.95M | -$39.90M | — | -113.7% |
| Basic shares | 63.59M | 63.45M | — | 63.23M | 63.14M | 62.97M | +0.2% |
| Diluted shares | 63.59M | 63.45M | — | 63.28M | 63.14M | 62.97M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $113.91M | $66.52M | $57.22M | $80.13M | $130.69M | — | +71.2% |
| Cash & short-term investments | $173.31M | $154.23M | $189.91M | $146.40M | $176.49M | — | +12.4% |
| Accounts receivable | $24.60M | $10.43M | $13.37M | $69.23M | $12.53M | — | +135.9% |
| Inventory | — | $9.50M | $7.91M | $8.75M | $9.28M | $9.43M | — |
| Total current assets | $321.69M | $182.52M | $219.94M | $232.09M | $204.94M | — | +76.2% |
| Property, plant & equipment | $23.53M | $33.97M | $35.52M | $37.28M | $39.07M | — | -30.7% |
| Total assets | $345.41M | $217.87M | $256.85M | $270.76M | $245.42M | — | +58.5% |
| Total current liabilities | $108.81M | $95.94M | $43.12M | $44.47M | $39.00M | — | +13.4% |
| Total debt | $35.09M | $36.51M | $36.76M | $37.01M | $37.25M | — | -3.9% |
| Total liabilities | $302.54M | $196.68M | $201.25M | $203.76M | $198.80M | — | +53.8% |
| Retained earnings | -$1.26B | -$1.28B | -$1.24B | -$1.23B | -$1.25B | — | +1.5% |
| Shareholder equity | $42.87M | $21.20M | $55.59M | $67.00M | $46.62M | — | +102.3% |
| Working capital | $212.87M | $86.58M | $176.83M | $187.62M | $165.94M | — | +145.9% |
| Net tangible assets | $42.87M | $21.20M | $55.59M | $67.00M | $46.62M | — | +102.3% |
| Shares issued | 63.65M | 63.56M | 63.32M | 63.26M | 63.21M | — | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $19.52M | -$36.77M | -$14.15M | $16.82M | -$36.25M | +153.1% |
| Depreciation & amortisation | $708.00K | $1.69M | $1.71M | $1.79M | $1.91M | -58.0% |
| Stock-based compensation | $1.97M | $2.65M | $2.66M | $3.55M | $3.69M | -25.4% |
| Change in working capital | -$17.74M | -$1.77M | $53.14M | -$52.24M | -$17.01M | -902.1% |
| Operating cash flow | -$40.75M | -$35.81M | $43.02M | -$30.19M | -$46.98M | -13.8% |
| Capital expenditure | -$806.00K | -$344.00K | -$244.00K | -$426.00K | -$715.00K | -134.3% |
| Investing cash flow | $27.96M | $45.32M | -$65.99M | -$20.37M | -$37.64M | -38.3% |
| Financing cash flow | $60.17M | -$207.00K | $57.00K | $0 | $69.74M | +29,169.1% |
| Free cash flow | -$41.55M | -$36.16M | $42.78M | -$30.61M | -$47.70M | -14.9% |
| End cash position | $113.91M | $66.52M | $57.22M | $80.13M | $130.69M | +71.2% |
Options analytics
Put / call volume
0.46
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
0.50
-86.3% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
+25.0%
Puts bid over calls
Call volume
41
Contracts, this expiry
Put volume
19
Contracts, this expiry
Heaviest call OI
6.00
28 contracts
Heaviest put OI
0.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.26 | 1.14 | +341.4% |
| Mar 2026 | -0.55 | -0.58 | -5.9% |
| Dec 2025 | -0.02 | -0.22 | -1,000.0% |
| Sep 2025 | -0.51 | 0.27 | +153.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.13 | 2 | $39.18M | -46.2% |
| Next quarter | -0.35 | 1 | $19.87M | -51.8% |
| Current year | -1.56 | 7 | $108.20M | -27.6% |
| Next year | -1.47 | 2 | $90.61M | -16.3% |
Analyst targets & ownership
Mean target$8.00
High target$11.00
Low target$4.00
Implied upside119.78%
Analyst count4
ConsensusBUY
Strong buy / Buy1 / 2
Hold4
Sell / Strong sell0 / 0
Held by insiders3.48%
Held by institutions77.62%
Institutions holding171
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.76
-3.24% from price
SMA 20
3.93
-7.30% from price
SMA 50
4.00
-8.89% from price
SMA 100
4.16
-12.41% from price
SMA 200
3.29
+10.73% from price
EMA 12
3.80
-4.30% from price
EMA 26
3.92
-7.11% from price
EMA 50
3.99
-8.70% from price
RSI (14)
41.6
Neutral
MACD (12,26,9)
-0.12
Hist -0.03
ATR (14)
0.22
6.17% of price
Realised vol 30D
62.3%
Annualised
Bollinger upper
4.32
20, 2σ
Bollinger lower
3.54
20, 2σ
50 / 200 cross
Golden
4.00 vs 3.29
Trend bias
Above 200
+10.73%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.93
Less volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
62.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-34.2%
Peak to trough
Max drawdown 5Y
-95.2%
Peak to trough
ATR 14
0.22
6.17% of price
Beta (reported)
1.21
5Y monthly, from filing
Short interest
Shares short
7.03M
Prior 7.26M
Change vs prior
-3.1%
Shorts covering
% of float
11.44%
Elevated
% of shares out
11.04%
Against total outstanding
Days to cover
16.2
Crowded exit
Float
56.42M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Apr 20, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Apr 10, 26 | B. Riley Securities | UPGRADE | Neutral | Buy |
| Mar 10, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Nov 3, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Aug 15, 25 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| May 20, 25 | B. Riley Securities | MAINTAINED | Neutral | Neutral |
| May 14, 25 | Stifel | MAINTAINED | Hold | Hold |
| May 14, 25 | Barclays | MAINTAINED | Overweight | Overweight |
| Mar 25, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Nov 7, 24 | JMP Securities | DOWNGRADE | Market Outperform | Market Perform |
| Nov 6, 24 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-8 · 2026-09-03
Periodic Financial Reports
10-Q · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-23
Corporate Changes & Voting Matters
8-K · 2026-07-08
Corporate Changes & Voting Matters
8-K · 2026-07-07
Corporate Changes & Voting Matters
8-K · 2026-05-20
Periodic Financial Reports
10-Q · 2026-05-13
Headlines
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Zacks · 14d ago
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 27d ago
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Zacks · 48d ago
B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating
MT Newswires · 51d ago
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
Insider Monkey · 53d ago
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 54d ago
MacroGenics: Q2 Earnings Snapshot
Associated Press · 54d ago
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
GlobeNewswire · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.